View in EDS HTML Full Text PDF Full Text

Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany.

Saved in:
Bibliographic Details
Title: Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany.
Authors: Basic E; Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany. edin.basic@takeda.com., Kappel M; Health Economics, WifOR, Darmstadt, Germany., Misra A; Health Economics, WifOR, Darmstadt, Germany., Sellner L; Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany., Ratsch BA; Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany., Ostwald DA; Health Economics, WifOR, Darmstadt, Germany.; School of International Business and Entrepreneurship (SIBE), Steinbeis University Berlin, Berlin, Germany.
Source: The European journal of health economics : HEPAC : health economics in prevention and care [Eur J Health Econ] 2020 Dec; Vol. 21 (9), pp. 1351-1361. Date of Electronic Publication: 2020 Jul 11.
Publication Type: Journal Article
Journal Info: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 101134867 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1618-7601 (Electronic) Linking ISSN: 16187598 NLM ISO Abbreviation: Eur J Health Econ Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32654072
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Basic+E%22">Basic E</searchLink>; Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany. edin.basic@takeda.com.<br /><searchLink fieldCode="AU" term="%22Kappel+M%22">Kappel M</searchLink>; Health Economics, WifOR, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Misra+A%22">Misra A</searchLink>; Health Economics, WifOR, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Sellner+L%22">Sellner L</searchLink>; Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Ratsch+BA%22">Ratsch BA</searchLink>; Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Ostwald+DA%22">Ostwald DA</searchLink>; Health Economics, WifOR, Darmstadt, Germany.; School of International Business and Entrepreneurship (SIBE), Steinbeis University Berlin, Berlin, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101134867%22">The European journal of health economics : HEPAC : health economics in prevention and care</searchLink> [Eur J Health Econ] 2020 Dec; Vol. 21 (9), pp. 1351-1361. <i>Date of Electronic Publication: </i>2020 Jul 11.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer-Verlag%22">Springer-Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>101134867 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1618-7601 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216187598%22">16187598 </searchLink><i>NLM ISO Abbreviation: </i>Eur J Health Econ <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32654072
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10198-020-01219-3
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1351
    Titles:
      – TitleFull: Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Basic E
      – PersonEntity:
          Name:
            NameFull: Kappel M
      – PersonEntity:
          Name:
            NameFull: Misra A
      – PersonEntity:
          Name:
            NameFull: Sellner L
      – PersonEntity:
          Name:
            NameFull: Ratsch BA
      – PersonEntity:
          Name:
            NameFull: Ostwald DA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2020 Dec
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 1618-7601
          Numbering:
            – Type: volume
              Value: 21
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: The European journal of health economics : HEPAC : health economics in prevention and care
              Type: main
ResultId 1